Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma

In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 μg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 μg of each HA, reactogenicity was minor. Among patients with similar preva...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2006-11, Vol.194 (10), p.1394-1397
Main Authors: Safdar, Amar, Rodriguez, M. Alma, Fayad, Luis E., Rodriguez, Gilhen H., Pro, Barbara, Wang, Michael, Romaguera, Jorge E., Goy, Andre H., Hagemeister, Fredrick B., McLaughlin, Peter, Bodey, Gerald P., Kwak, Larry W., Raad, Issam I., Couch, Robert B.
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Viral - blood
B cell lymphoma
Baculoviridae - genetics
Biological and medical sciences
Dosage
Dose response relationship
Dose-Response Relationship, Immunologic
Double-Blind Method
Female
Fundamental and applied biological sciences. Psychology
Hemagglutinins, Viral - genetics
Hemagglutinins, Viral - immunology
Human viral diseases
Humans
Infectious diseases
Influenza A virus
Influenza A Virus, H1N1 Subtype - immunology
Influenza A Virus, H3N2 Subtype - immunology
Influenza B virus - immunology
Influenza vaccines
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Lymphoma, B-Cell - immunology
Male
Medical sciences
Microbiology
Middle Aged
Neutralization Tests
Neutralizing antibodies
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - adverse effects
Vaccines, Synthetic - immunology
Viral diseases
Viral diseases of the respiratory system and ent viral diseases
Viral Proteins - genetics
Viral Proteins - immunology
Virology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 μg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 μg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 μg and 60% given 135 μg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135-μg vaccine
ISSN:0022-1899
1537-6613
DOI:10.1086/508493